Ocular Therapeutix, Inc. (OCUL) Covered Calls
Ocular Therapeutix is a biopharmaceutical company developing innovative therapies for eye diseases. Using its proprietary bioresorbable hydrogel platform, the company creates sustained-release drug delivery solutions. Its portfolio includes treatments for post-surgical inflammation and allergic conjunctivitis, plus a pipeline for glaucoma and wet AMD.
You can sell covered calls on Ocular Therapeutix, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for OCUL (prices last updated Tue 12:35 PM ET):
| Ocular Therapeutix, Inc. (OCUL) Stock Quote | ||||||
|---|---|---|---|---|---|---|
| Last | Change | Bid | Ask | Volume | P/E | Market Cap |
| 10.03 | +0.08 | 10.02 | 10.03 | 1.6M | - | 2.2 |
| Covered Calls For Ocular Therapeutix, Inc. (OCUL) | ||||||
|---|---|---|---|---|---|---|
| Expiration | Strike | Call Bid | Net Debit | Return If Flat |
Annualized Return If Flat |
|
| Mar 20 | 10 | 0.50 | 9.53 | 4.9% | 163% | |
| Apr 17 | 10 | 1.10 | 8.93 | 12.0% | 112% | |
| Subscribers get access to the full covered call chain, and more features. | ||||||
Want to make money with covered calls? Sign Up For A Free Trial
Ocular Therapeutix, Inc. is a biopharmaceutical company dedicated to the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye. The company leverages its proprietary ELUTYX technology platform, a bioresorbable hydrogel-based formulation, to provide sustained-release delivery of therapeutic agents, potentially replacing traditional eye-drop regimens with more consistent and convenient treatment options.
Core Business and Products
- DEXTENZA: The company's lead commercial product is an FDA-approved corticosteroid insert placed in the punctum to treat post-surgical ocular inflammation and pain, as well as ocular itching associated with allergic conjunctivitis.
- AXPAXLI: A clinical-stage intravitreal implant being developed for the treatment of wet age-related macular degeneration (wet AMD). It is designed to provide sustained release of axitinib over several months.
- PAXTRAVA: A sustained-release travoprost implant currently in clinical trials for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Competitive Landscape
The ophthalmic pharmaceutical market is highly competitive, characterized by rapid technological advancement. Ocular Therapeutix competes with large-scale pharmaceutical firms and specialized biotechnology companies. Key competitors include Regeneron Pharmaceuticals Inc and Bausch Health Companies, which offer established treatments for retinal diseases and inflammation. The company also faces competition from EyePoint Pharmaceuticals Inc and Aldeyra Therapeutics in the development of sustained-release delivery systems and novel ocular therapies. Other significant players in the space include Alcon and Novartis.
Strategic Outlook and Innovation
The company is focused on expanding its pipeline by applying its hydrogel technology to a broader range of front- and back-of-the-eye indications. A primary strategic priority is the advancement of the registrational clinical program for its wet AMD candidate, aiming to offer a differentiated treatment profile that reduces the frequency of intraocular injections. Additionally, the company is exploring the use of its platform for the treatment of diabetic retinopathy. By focusing on sustained-release technology, the company aims to improve patient compliance and clinical outcomes while reducing the overall treatment burden for chronic eye conditions.
| Top 10 Open Interest For Mar 20 Expiration | Top 5 High Yield | |||||
|---|---|---|---|---|---|---|
| 1. | NVDA covered calls | 6. | QQQ covered calls | 1. | CTMX covered calls | |
| 2. | SLV covered calls | 7. | EWZ covered calls | 2. | PATH covered calls | |
| 3. | EEM covered calls | 8. | FXI covered calls | 3. | FLY covered calls | |
| 4. | SPY covered calls | 9. | GLD covered calls | 4. | FJET covered calls | |
| 5. | IBIT covered calls | 10. | KWEB covered calls | 5. | ORCL covered calls | |
Want more examples? OCSL Covered Calls | ODD Covered Calls
Risk Disclosure: Trading options involves significant risk and is not suitable for all investors. The information provided on this website is for educational and informational purposes only and does not constitute financial, investment, tax, or legal advice. Nothing contained on this site is an offer to buy or sell, or a solicitation of an offer to buy or sell, any securities or financial instruments.
Covered Call Strategy Risks: While covered call writing is often considered a conservative options strategy, it is not without risk. By selling a covered call, you are limiting your potential upside profit from the underlying stock. You remain exposed to the full downside risk of owning the underlying stock. In the event of a significant decline in the stock price, the premium received may not be sufficient to offset your losses.
No Guarantee of Performance: Past performance is not indicative of future results. Any examples, calculations, or hypothetical scenarios presented on this site are for illustrative purposes only and do not guarantee future returns or outcomes. Market conditions, liquidity, and trading system failures can affect your ability to execute trades at desired prices.
You should consult with a qualified professional advisor and conduct your own due diligence before making any investment decisions. By using this website, you acknowledge that you are responsible for your own investment decisions and agree to release this site and its affiliates from any liability relating to your use of this information. See the OCC's Characteristics and Risks of Standardized Options for more info.
